CBN and sleep: primary and secondary endpoints

Abstract-limited review: the full primary article was not accessible for this packet. The available abstract describes 20 adults with diagnosed insomnia in a randomized placebo-controlled crossover trial, with one night per condition. Detailed preparation purity, full analysis and protocol concordance remain unverified. This guide is an endpoint-reading example, not a complete CBN treatment review.

Neither CBN condition significantly changed the primary wake-after-sleep-onset outcome. Reported uncertainty intervals included no difference. That does not demonstrate that every possible effect is zero; it does mean the abstract does not establish primary-endpoint success.

The abstract reports favorable secondary sleep findings in one condition. Secondary findings do not replace the main outcome, and detailed multiplicity and analysis choices were unavailable for independent full-text checking. One-night observations cannot establish chronic insomnia benefit or equivalence across retail CBN formulations.

The abstract reports mild-to-moderate adverse events across all conditions, but arm-specific attribution and detailed serious-event reporting remain held. An event count is not a count of affected people. Funding allocation was not verified from the accessible abstract; author industry disclosures should not be misreported as this trial’s funding.